◆英語タイトル:CEL-SCI Corp (CVM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C13086
◆発行会社(調査会社):
GlobalData
◆発行日:2019年1月
◆ページ数:44
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
CEL-SCI Corp (CVM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
CEL-SCI Corp (CEL-SCI) is a biotechnology company that carries out the research and development of new immunotherapy products for the treatment of various cancer and infectious diseases. Its core capabilities include drug discovery, research, development and manufacturing of compound biological substances. CEL-SCI’s lead candidate Multikine (leukocyte interleukin), is an investigational immunotherapy against cancer and human papilloma virus (HPV). The company is also investigating an immunotherapy (LEAPS-H1N1-DC) as a possible treatment for H1N1 in hospitalized patients and vaccines CEL-2000 and CEL-4000 for rheumatoid arthritis using its Ligand Epitope Antigen Presentation System (LEAPS) technology platform. CEL-SCI is headquartered in Vienna, Virginia, the US.
CEL-SCI Corp Key Recent Developments
Dec 20,2018: CEL-SCI announces fiscal 2018 financial results and clinical & corporate developments
Aug 17,2018: CEL-SCI Announces that the NYSE American approves plan
Aug 14,2018: CEL-SCI reports third quarter fiscal year 2018 financial results
Jun 28,2018: CEL-SCI Announces $5 Million Registered Direct Offering
Jun 11,2018: CEL-SCI Issues Letter to Shareholders
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 – About the Company 5
CEL-SCI Corp – Key Facts 5
CEL-SCI Corp – Key Employees 6
CEL-SCI Corp – Key Employee Biographies 7
CEL-SCI Corp – Major Products and Services 8
CEL-SCI Corp – History 9
CEL-SCI Corp – Company Statement 13
CEL-SCI Corp – Locations And Subsidiaries 14
Head Office 14
Section 2 – Company Analysis 15
Company Overview 15
CEL-SCI Corp – Business Description 16
CEL-SCI Corp – Corporate Strategy 17
CEL-SCI Corp – SWOT Analysis 18
SWOT Analysis – Overview 18
CEL-SCI Corp – Strengths 18
CEL-SCI Corp – Weaknesses 19
CEL-SCI Corp – Opportunities 20
CEL-SCI Corp – Threats 21
CEL-SCI Corp – Key Competitors 22
Section 3 – Company Financial Ratios 23
Financial Ratios – Capital Market Ratios 23
Financial Ratios – Annual Ratios 24
Performance Chart 26
Financial Performance 26
Financial Ratios – Interim Ratios 27
Financial Ratios – Ratio Charts 28
Section 4 – Company’s Lifesciences Financial Deals and Alliances 29
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
CEL-SCI Corp, Recent Deals Summary 31
Section 5 – Company’s Recent Developments 32
Aug 17, 2018: CEL-SCI Announces that the NYSE American approves plan 32
Aug 14, 2018: CEL-SCI reports third quarter fiscal year 2018 financial results 33
Jun 28, 2018: CEL-SCI Announces $5 Million Registered Direct Offering 34
Jun 11, 2018: CEL-SCI Issues Letter to Shareholders 35
Apr 04, 2018: CEL-SCI: Letter to Shareholders 36
Feb 12, 2018: CEL-SCI Reports First Quarter Fiscal 2018 Financial Results 37
Jan 03, 2018: CEL-SCI Releases Letter to Shareholders 38
Section 6 – Appendix 40
Methodology 40
Ratio Definitions 40
About GlobalData 44
Contact Us 44
Disclaimer 44
List of Tables
CEL-SCI Corp, Key Facts 5
CEL-SCI Corp, Key Employees 6
CEL-SCI Corp, Key Employee Biographies 7
CEL-SCI Corp, Major Products and Services 8
CEL-SCI Corp, History 9
CEL-SCI Corp, Key Competitors 22
CEL-SCI Corp, Ratios based on current share price 23
CEL-SCI Corp, Annual Ratios 24
CEL-SCI Corp, Annual Ratios (Cont...1) 25
CEL-SCI Corp, Interim Ratios 27
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019 30
CEL-SCI Corp, Recent Deals Summary 31
Currency Codes 40
Capital Market Ratios 40
Equity Ratios 41
Profitability Ratios 41
Cost Ratios 42
Liquidity Ratios 42
Leverage Ratios 43
Efficiency Ratios 43
List of Figures
CEL-SCI Corp, Performance Chart (2014 - 2018) 26
CEL-SCI Corp, Ratio Charts 28
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019 29
CEL-SCI Corp, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019 30